A new guideline from the American Society of Clinical Oncology (ASCO) was released January 22nd, 2025, updating care for women with advanced-stage ovarian, fallopian tube, or primary peritoneal cancer. Recommendations included that these patients should be evaluated by a gynecologic oncologist before starting treatment to determine if they are candidates for primary cytoreductive surgery (meaning surgery to remove as much tumor as possible before starting treatment). They also recommended that germline and somatic testing for BRCA1 and BRCA2 as well as germline testing for other ovarian cancer susceptibility genes should be done. These updates reinforce the importance of genetic testing and specialized evaluation in treatment planning, ensuring patients receive the most effective and personalized care.
Gaillard, et al. J Clin Oncol. 2025;43(7):868-891. PMID: 39841949. Article available at: https://ascopubs.org/doi/10.1200/JCO-24-02589. Social media post available at: https://tinyurl.com/post2072025.